A recent ceremony marked the completion of the basic structure of the newest major addition to the University of Oxford estate, which will hold commercialisation facilities and an innovative collaborative research centre aimed at transforming diabetes treatments.
The Novo Nordisk Research Centre is the result of a strategic alliance between the University and the Danish healthcare company, first announced in January 2017. The company is currently in temporary offices at the nearby Wellcome Trust Centre for Human Genetics, but 80-100 staff will move into the new building once it is finished, expected to be in mid-2018. They will work closely with academics to develop new approaches to diabetes care.
The building will also hold a car park and the BioEscalator, which will facilitate the commercialisation of the University’s biotechnology research. James Johnson, VP and site head at Novo Nordisk, joined Dr Elen Wade-Martins of the BioEscalator to tighten bolts on the building’s roof, marking the completion of its highest point.